Association between combat-related traumatic injury and cardiovascular risk

Christopher J Boos 1,2,3,4, Susie Schofield,5 Paul Cullinan,5 Daniel Dyball,1,2 Nicola T Fear,5 Anthony M J Bull,5 David Pernet,2 Alexander N Bennett,1,5 for the ADVANCE study

ABSTRACT

Objective The association between combat-related traumatic injury (CRTI) and cardiovascular risk is uncertain. This study aimed to investigate the association between CRTI and both metabolic syndrome (MetS) and arterial stiffness.

Methods This was a prospective observational cohort study consisting of 579 male adult UK combat veterans (UK-Afghanistan War 2003–2014) with CRTI who were frequency-matched to 565 uninjured men by age, service, rank, deployment period and role-in-theatre. Measures included quantification of injury severity (New Injury Severity Score (NISS)), visceral fat area (dual-energy X-ray absorptiometry), arterial stiffness (heart rate–adjusted central augmentation index (cAlx)) and pulse wave velocity (PWV), fasting venous blood glucose, lipids and high-sensitivity C reactive protein (hs-CRP).

Results Overall the participants were 34.1±5.4 years, with a mean (±SD) time from injury/deployment of 8.3±2.1 years. The prevalence of MetS (18.0% vs 11.8%; adjusted risk ratio 0.83, 95% CI 0.70 to 0.98) and the mean cAlx (17.61%±8.79% vs 11.8%; adjusted risk ratio 1.46, 95% CI 1.10 to 1.94, p<0.0001) were higher among the CRTI versus the uninjured group, respectively. Abdominal waist circumference, visceral fat area, triglycerides, estimated insulin resistance and hs-CRP levels were greater and physical activity and high-density lipoprotein–cholesterol lower with CRTI. There were no significant between-group differences in blood glucose, blood pressure or PWV. CRTI, injury severity (TNISS), age, socioeconomic status (SEC) and physical activity were independently associated with both MetS and cAlx.

Conclusions CRTI is associated with an increased prevalence of MetS and arterial stiffness, which are also influenced by age, injury severity, physical activity and SEC. The longitudinal impact of CRTI on clinical cardiovascular events needs further examination.

INTRODUCTION

The long-term health outcomes of survivors of combat-related traumatic injury (CRTI) are unclear. It has been reported that severe CRTI may be associated with an increased risk of cardiovascular disease (CVD) and major adverse cardiovascular events (MACE).1–3 However, a recent systematic review and meta-analysis has shown that the strength of this evidence is modest, at best, and derived from retrospective studies relating to injuries sustained ≥40 years ago or from small cross-sectional studies with poorly defined control groups.4 There is a need for a contemporary prospective cohort study examining the relationship between CRTI and its severity to earlier markers of cardiovascular risk, which if established would prompt prevention strategies to mitigate the risk.5

Metabolic syndrome (MetS) and arterial stiffness are two recognised markers of cardiovascular risk. MetS affects up to 30% of Western adults, with a prevalence that is rapidly rising.6 MetS is associated with increased arterial stiffness and MACE.7,8 Among the measures of arterial stiffness, pulse wave velocity (PWV) remains the gold standard. However, there is increasing interest in central augmentation index (cAlx), which may be a more sensitive marker of early arterial stiffness and endothelial dysfunction.9,10 Moreover, increased cAlx has been linked to all-cause mortality and MACE. Two recent studies have reported an association between CRTI and MetS;11,12 They were both retrospective and did not include an uninjured comparison group. The relationship between CRTI and arterial stiffness has not been examined.

The ADVANCE (Armed ServiceA CenTrauM Reha- bilitation OutComE) study seeks to address these knowledge gaps in a contemporary population with CRTI. This baseline analysis of the ADVANCE cohort aimed to investigate, for the first time, the relationship between CRTI, MetS and arterial stiffness.

METHODS

Study design

The ADVANCE study is a prospective cohort study designed to investigate the long-term health outcomes of British combat casualties who sustained CRTI during recent military operations in Afghanistan (2003–2014). Details of the study design, sampling and protocol have been previously published.4 The primary outcomes were the relative prevalence of MetS and large artery stiffness (using cAlx) among injured versus uninjured servicemen.

Study population

Between March 2016 and August 2020, male UK military personnel (≥18 years) who had sustained CRTI (sufficient to require aeromedical evacuation) were compared with a frequency-matched comparison group (by age, service, rank, regiment, deployment period and role-in-theatre) of
uninjured servicemen. Identification and sampling of the injured and uninjured groups were undertaken by the Defence Statistics (Health) within the UK Ministry of Defence using deployment and medical records.

Participants with established CVD (history of stroke or transient ischaemic attack, ischaemic heart disease (IHD), peripheral vascular disease) prior to their injury/deployment of interest or evidence of active acute infection at baseline survey were excluded.5

Patients and the public were engaged, and continue to be so, in the study design, research questions, outcome measures, conduct and logistics of the study via focus groups, feedback questionnaires, newsletters and via the ADVANCE study website (https://www.advancestudydmrc.org.uk). Study participation was voluntary and following full informed consent.

Biometric data and blood tests

Prior to the baseline study visit, participants were asked to fast and refrain from caffeine and alcohol for at least 8 hours. Questionnaires were completed during a clinical interview with a trained research nurse; data included confirmation of the participant’s ethnicity, medical and family history (of stroke or IHD) and smoking status. Baseline measures included height, participant’s ethnicity, medical and family history (of stroke or transient ischaemic attack, ischaemic heart disease (IHD), peripheral vascular disease) prior to their injury/deployment of interest or evidence of active acute infection at baseline survey were excluded.5

Blood glucose, glycated haemoglobin (HbA1c), lipid level, high-sensitivity C reactive protein (hs-CRP; lower detection limit 0.10 mg/L) and full blood count were measured in venous blood processed by the local hospital laboratory.

Diagnosis of MetS and assessment of insulin resistance

The presence of MetS was established (binary yes/no) in accordance with the American Heart Association criteria of three out of the following five: (1) central obesity (AWC ≥102 cm), (2) triglycerides ≥1.7 mmol/L, (3) high-density lipoprotein (HDL)-cholesterol <1.03 mmol/L, (4) blood pressure ≥130/85 mm Hg (or treated for hypertension) and (5) fasting plasma glucose ≥5.6 mmol/L.7

Insulin resistance was assessed using the estimated glucose disposal rate (eGDR) calculated as the following: eGDR mg/kg/min=21.158+(-0.09×AWC (cm))+(-3.407×hypertension (yes=1, no=0))+(−0.551×HbA1c %).14 A lower eGDR is indicative of greater relative insulin resistance.14

Assessment of injury severity and socioeconomic class

The severity of the original CRTI was quantified using the New Injury Severity Score (NISS),15 provided by the UK Joint Theatre Trauma Registry, which is a prospectively collected database of every service casualty admitted to a deployed UK medical facility.6

Socioeconomic status (SEC) was classified by military rank at the time of deployment using the three-tier National Statistics Socio-Economic Classification (NS-SEC): senior rank (commissioned officers), NS-SEC group 1; mid-rank (senior non-commissioned officers), NS-SEC group 2; and junior rank

### Table 1 Baseline demographics among uninjured versus CRTI participants

| Uninjured vs CRTI | CRTI by NISS category |
|-------------------|----------------------|
| Number            | NISS <13         | NISS ≥13       |
| Number            | Uninjured | CRTI      | P value† | Uninjured | CRTI      | P value‡ |
| 565               | 579        | –         | 288      | 291       | –         | 25.82±5.45 | 25.61±4.87 | 0.53      |
| Age at sampling, years | 26.02±5.07 | 25.71±5.16 | 0.31     | 25.82±5.45 | 25.61±4.87 | 0.53      |
| Age at assessment, years | 34.24±5.41 | 34.01±5.35 | 0.49     | 34.49±5.48 | 33.54±5.18 | 0.08      |
| Time from deployment/ injury to assessment, years | 8.2±2.15 | 8.33±2.14 | 0.36     | 8.70±2.08 | 7.96±2.15 | 0.0001‡§ |
| Still serving in military | 454 (80.4) | 159 (27.5) | <0.0001 | 110 (38.2) | 49 (16.8) | <0.0001 |
| Rank/NS-SEC (at sampling) | Senior rank (NS-SEC 1) | 79 (14.0) | 60 (10.4) | <0.001 | 28 (9.7) | 32 (11.0) | 0.20 |
| | Mid-rank (NS-SEC 2) | 147 (26.0) | 106 (18.3) |       | 61 (21.2) | 45 (15.5) |       |
| | Lower rank (NS-SEC 3) | 339 (60.0) | 413 (71.3) |       | 199 (69.1) | 214 (73.5) |       |
| Injury mechanism | Blast | – | 435 (75.1) | – | 201 (69.8) | 234 (80.4) |       | 0.010 |
| | On-blast (accidents, gunshot, burns) | – | 144 (24.9) | – | 87 (30.2) | 57 (19.6) |       |       |
| Injury type: limb amputation | – | 161 (27.8) | 17 (5.9) | 144 (49.5) | <0.0001§¶ |       |       |
| NISS, median (IQR) | – | 13.0 (5.0–30.0) | – | 5.0 (3.0–9.0) | 29.0 (20.0–45.0) | <0.0001               |
| Ethnicity: Caucasian | 512 (90.6) | 525 (90.6) | 1.0     | 259 (89.9) | 265 (91.1) | 0.75     |
| Family history of CVD* | 111 (19.6) | 106 (18.3) | 0.60    | 53 (18.4) | 53 (18.28) | 0.85     |
| Smoking history | Current smoker | 126 (22.3) | 119 (20.6) | – | 66 (22.9) | 53 (18.2) |       | 0.37 |
| | Ex-smoker | 178 (31.5) | 168 (29.0) | – | 84 (29.2) | 84 (28.9) |       |       |
| | Never | 261 (46.2) | 292 (50.4) | 0.36 | 138 (47.9) | 154 (52.9) |       |       |

Data presented as mean±SD or number (%) unless otherwise stated.
*Defined as history of stroke of confirmed coronary heart disease in one or more first-degree relative.
†Tests the difference between CRTI and uninjured.
‡Tests the difference between uninjured (where applicable), NISS <13 and NISS ≥13.
§Significant (p<0.05) post-hoc differences: uninjured vs NISS <13.
¶Significant (p<0.05) post-hoc differences: NISS <13 vs NISS ≥13.
CRTI, combat-related traumatic injury; CVD, cardiovascular disease; NISS, New Injury Severity Score; NS-SEC, National Statistics Socio-Economic Classification.
Body composition assessment and physical fitness

Visceral fat area was measured using dual-energy X-ray absorptiometry (Vertec Horizon and Discovery, UK). Total weekly leisure time physical activities were quantified using the International Physical Activity Questionnaire and graded according to the WHO weekly recommendation of ≥150 min of moderate and/or >75 min of vigorous exercise. Physical function was measured using the 6 min walk distance (6MWD) test.

**Measurement of arterial stiffness and blood pressure**

Arterial stiffness and central blood pressures were measured using a Vicorder device (Skidmore Medical, UK). Measurements were undertaken by trained research nurses in a blinded manner.

### Table 2 Comparative anthropometric indices and venous blood results of uninjured versus CRTI participants

| Characteristic                                  | Uninjured vs CRTI | CRTI by NISS category |
|-------------------------------------------------|-------------------|------------------------|
|                                                | Uninjured         | CRTI                   | NISS <13 | NISS ≥13 | P value* |
| Height, cm                                      | 178.8±6.4         | 179.3±7.1              | 0.25     |          |          |
| Body mass, kg                                   | 87.85±12.24       | 90.56±14.38            | 0.0006   |          |          |
| Waist circumference, cm                         | 93.48±9.97        | 95.72±10.17            | 0.0002   |          |          |
| Visceral fat area, cm²                          | 83.0 (66.5–108.5) | 91.0 (70.0–120.0)      | 0.0002   |          |          |
| Haemoglobin, g/L                                | 152.40±8.77       | 152.10±9.83            | 0.68     |          |          |
| Platelet count, x10^11/L                        | 234.0±45.10       | 241.4±60.43            | 0.02     |          |          |
| White cell count, x10^9/L                       | 5.58±1.35         | 5.74±1.73              | 0.07     |          |          |
| hs-CRP, mg/L                                    | 0.85 (0.50–1.76)  | 1.02 (0.50–2.10)       | 0.02     |          |          |
| Total cholesterol, mmol/L                       | 5.02±0.97         | 4.93±0.99              | 0.09     |          |          |
| LDL-cholesterol, mmol/L                         | 1.31±0.30         | 1.26±0.32              | 0.02     |          |          |
| Triglycerides, mmol/L                           | 1.30±0.94         | 1.40±0.95              | 0.02     |          |          |
| Glucose, mmol/L                                 | 4.95±0.66         | 5.01±1.32              | 0.43     |          |          |
| HbA1c, mmol/mol                                 | 34.60±3.79        | 34.72±8.35             | 0.76     |          |          |
| eGDR, mg/kg/min                                 | 10.21±0.93        | 9.98±1.08              | 0.0002   |          |          |
| Metabolic syndrome, n (%)                       | 66/558 (11.8)     | 102/567 (18.0)         | 0.004    |          |          |

*Tests the difference between CRTI and uninjured.
†Tests the difference between uninjured, NISS <13 and NISS ≥13.
‡Significant (p<0.05) post-hoc difference: uninjured vs NISS <13.
§Significant (p<0.05) post-hoc difference: uninjured vs NISS ≥13.
¶Significant (p<0.05) post-hoc difference: NISS <13 vs NISS ≥13.

CRTI, combat-related traumatic injury; eGDR, estimated glucose disposal rate; HbA1c, glycated haemoglobin; LDL, high-density lipoprotein; hs-CRP, high-sensitivity C reactive protein; NISS, New Injury Severity Score.

### Table 3 Comparative haemodynamic and exercise data between uninjured and CRTI participants

| Characteristic                                  | Uninjured vs CRTI | CRTI by NISS category |
|-------------------------------------------------|-------------------|------------------------|
|                                                | Uninjured         | CRTI                   | NISS <13 | NISS ≥13 | P value** |
| Heart rate, per minute                          | 56.27±8.38        | 59.91±9.99             | <0.0001  |          |          |
| Brachial systolic blood pressure, mm Hg         | 132.0±11.44       | 131.4±11.07            | 0.14     |          |          |
| Brachial diastolic blood pressure, mm Hg        | 2.06±8.25         | 71.79±8.81             | 0.60     |          |          |
| Mean brachial arterial pressure, mm Hg          | 94.68±6.68        | 94.69±8.91             | 0.99     |          |          |
| Aortic systolic blood pressure, mm Hg           | 127.2±11.88       | 126.6±11.74            | 0.37     |          |          |
| Central augmentation index, %*                  | 15.20±8.20        | 17.59±8.77             | <0.0001  |          |          |
| Pulse wave velocity, m/s                        | 8.11±1.61         | 8.23±1.95              | 0.26     |          |          |
| Stroke volume index, ml/m²†                     | 55.47±10.79       | 53.10±11.33            | 0.003    |          |          |
| Cardiac index, L/m²†                            | 3.10±0.63         | 3.14±0.68              | 0.25     |          |          |
| Physical activity recommendation, %§            | 351/536 (65.5)    | 315/548 (57.5)         | 0.007    |          |          |
| 6 min walk distance, m                          | 630.6±95.69       | 538.1±173.8            | <0.0001  |          |          |

*Corrected for resting heart rate.
†Calculated as the stroke volume divided by body surface area.
‡Calculated as SVI×resting heart rate.
§Defined as >150 min of moderate or >75 min of vigorous weekly physical exercise.
¶Tests the difference between CRTI and uninjured.
**Tests the difference between uninjured, NISS <13 and NISS ≥13.
††Significant (p<0.05) post-hoc differences: uninjured vs NISS <13.
‡‡Significant (p<0.05) post-hoc differences: uninjured vs NISS ≥13.
§§Significant (p<0.05) post-hoc differences: NISS <13 vs NISS ≥13.

CRTI, combat-related traumatic injury; NISS, New Injury Severity Score; SVI, stroke volume index.
Cardiac risk factors and prevention

Table 4  Comparative prevalence of metabolic syndrome defining criteria (yes/no) in relation to CRTI and injury severity (NISS)

| Characteristics                          | Uninjured vs injured | Injury by NISS | P value* | NISS <13 (n=288) | NISS ≥13 (n=291) | P value† |
|------------------------------------------|----------------------|---------------|----------|-----------------|-----------------|----------|
| Waist circumference >103 cm              | 115/565 (20.4)       | 166/579 (28.7) | 0.001    | 79/288 (27.4)   | 87/291 (29.9)   | 0.004    |
| High-density lipoprotein <1.03 mmol/L    | 98/560 (17.5)        | 148/568 (26.1) | 0.005    | 57/283 (20.1)   | 91/285 (31.9)   | <0.0001  |
| Triglycerides >1.7 mmol/L                | 114/561 (20.3)       | 149/568 (26.2) | 0.02     | 70/283 (24.7)   | 79/285 (27.7)   | 0.04     |
| Fasting glucose >5.6 mmol/L             | 43/532 (8.1)         | 49/554 (8.8)   | 0.61     | 28/275 (10.2)   | 21/279 (7.5)    | 0.50     |
| Blood pressure >130/85 mm Hg            | 303/564 (52.7)       | 290/577 (50.2) | 0.26     | 157/287 (54.7)  | 133/290 (45.9)  | 0.05     |

χ² results are presented.
*Tests the difference between those with and without metabolic syndrome.
†Tests the difference between uninjured, NISS <13 and NISS ≥13.
‡Only applies to the injured portion of the cohort.

Table 5  Demographics and biomarkers by presence or absence of metabolic syndrome

| Metabolic syndrome | No (n=976) | Yes (n=168) | P value* |
|--------------------|------------|-------------|----------|
| Age at assessment, years | 33.89±5.27 | 35.50±5.78 | 0.0003   |
| Rank/NS-SEC (at sampling), n (%) | | | |
| Senior rank (NS-SEC 1) | 129 (13.2) | 10 (5.9) | 0.03     |
| Mid-rank (NS-SEC 2) | 213 (21.8) | 40 (23.8) | 0.60     |
| Junior rank (NS-SEC 3) | 634 (65.0) | 118 (70.2) | 0.48     |
| Caucasian, n (%) | 881/976 (90.2) | 155/168 (92.3) | 0.48     |
| Time from exposure/injury, years | 8.28±2.17 | 8.19±2.0 | 0.60     |
| Physical activity recommendation†, n (%) | 598/927 (64.5) | 68/157 (43.3) | <0.0001  |
| 6 min walk distance | 594.6±139.40 | 520.61±179.20 | <0.0001  |
| eGDR, mg/kg/min | 10.30±0.85 | 8.92±1.10 | <0.0001  |
| hs-CRP, mg/L | 0.80 (0.45–1.70) | 1.73 (1.0–3.60) | <0.0001  |
| New Injury Severity Score | 12.0 (5.0–29.0) | 22.0 (6.0–41.0) | 0.012    |
| Heart rate, min | 57.09±8.79 | 64.05±10.63 | <0.0001  |
| Brachial systolic blood pressure, mm Hg | 130.3±10.96 | 138.7±11.67 | <0.0001  |
| Aortic systolic blood pressure, mm Hg | 125.4±11.20 | 135.5±11.54 | <0.0001  |
| Central augmentation index, % | 15.43±8.45 | 22.1±6.92 | <0.0001  |
| Pulse wave velocity, m/s | 8.13±1.82 | 8.38±1.60 | 0.010    |

*Tests the difference between those with and without metabolic syndrome.
†Only applies to the injured portion of the cohort.
eGDR, estimated glucose disposal rate; hs-CRP, high-sensitivity C reactive protein; NS-SEC, National Statistics Socio-Economic Classification.

Statistical analysis
Continuous data were presented as mean (SD), or where their distribution was skewed by median (IQR). Unpaired t-test or Mann-Whitney U test, as appropriate, was used in two-group comparisons of continuous data; three-group comparisons were made using one-way analysis of variance or Kruskal-Wallis test with Tukey and Dunn post-hoc tests, respectively. χ² or Fisher’s exact tests were used to compare categorical data. Correlations were measured using Pearson or Spearman rank coefficients (95% CI) for continuous variables.

The relationship between CRTI (yes/no), its severity (NISS) and cAIx was examined using multivariable linear regression analyses. Plots of the residuals were visually inspected and variance inflation factors checked to assess model fit and any violation of assumptions. A modified Poisson regression (with a robust error variance) was used to estimate risk ratio (RR) and 95% CI to assess the association between CRTI (yes/no), CRTI severity and MetS (which is recommended when events are common; >10%). The influence of injury severity was investigated using the median NISS.

Given their recognised associations with MetS and cAIx, we adjusted, a priori, for the following pre-exposure confounders:

Table 6  Correlations between variables and central augmentation index

| Central augmentation index | Correlation coefficient (95% CI) | P value |
|---------------------------|---------------------------------|--------|
| Age                       | 0.22 (0.16 to 0.28)             | <0.0001|
| 6 min walk distance, m    | −0.17 (−0.23 to −0.12)          | <0.0001|
| Abdominal waist circumference | 0.40 (0.35 to 0.45)            | <0.0001|
| Visceral fat, %           | 0.48 (0.44 to 0.53)             | <0.0001|
| Total cholesterol, mmol/L | 0.14 (0.08 to 0.20)             | <0.0001|
| Triglycerides, mmol/L     | 0.34 (0.28 to 0.39)             | <0.0001|
| HDL-cholesterol, mmol/L   | −0.23 (−0.29 to −0.18)          | <0.0001|
| Glucose, mmol/L           | 0.20 (0.14 to 0.26)             | <0.0001|
| eGDR, mg/kg/min           | −0.40 (−0.45 to 0.035)          | <0.0001|
| hs-CRP, mg/L              | 0.26 (0.20 to 0.31)             | <0.0001|
| Brachial systolic blood pressure, mm Hg | 0.23 (0.17 to 0.28) | <0.0001|
| Aortic systolic blood pressure, mm Hg | 0.13 (0.08 to 0.19) | <0.0001|
| Pulse wave velocity, m/s  | 0.35 (0.30 to 0.40)             | <0.0001|
| eGDR, estimated glucose dispersion rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C reactive protein. |
age, ethnicity (Caucasian vs non-Caucasian) and SEC. Injury severity, physical activity and time from injury/deployment were also adjusted for in order to allow for any systematic differences in this variable.

Multiple imputation methods were not used as there were very few (<5%) missing data and complete case analyses were undertaken. Sensitivity analyses (not shown) to take account of undersampling of the less severely injured participants with blast injury were both greater in those with higher NISS than lower (NISS <13) trauma scores. The proportions of amputees and participants with blast injury were both greater in those with higher NISS compared to those with lower NISS. The proportions of amputees and participants with blast injury were both greater in those with higher NISS than lower (NISS <13) trauma scores. The proportions of amputees and participants with blast injury were both greater in those with higher NISS than lower (NISS <13) trauma scores.

A two-tailed p<0.05 was considered statistically significant. Statistical analyses were undertaken with SPSS V.26.0 and GraphPad Prism V.6.07 for Windows (GraphPad Software, San Diego, California, USA).

**RESULTS**

**Description of the study population**

The final sample comprised 1144 men (579 with CRTI, 50.6%) with a mean age of 26.1±5.2 years at the time of their injury or relevant deployment and 34.1±5.4 years at baseline assessment. The mean time from injury/deployment was 8.3±2.1 years. The adjusted response rates (excluding those who had died, had no known contact details or for whom no contact was attempted) were 59.6% and 56.3% for the injured and the uninjured group, respectively (p=0.56). The respondents in each group were similar in terms of age, ethnicity, height, family history of CVD, smoking history and time from deployment/injury to assessment (table 1). Compared with the uninjured group, the CRTI group were less likely to be still serving and were of lower SEC/rank (table 1). For those in the CRTI group, blast was the most common mechanism of injury, followed by gunshot wounds and other causes (eg, vehicular accidents, falls, etc). There were 161 men (27.8% of the CRTI group) with limb amputations (table 1). The median NISS was 13.0 (IQR, 5.0–30.0), with scores ranging from 1 to 75 (online supplemental figure 1). Among the CRTI group there were 288 participants with an NISS of <13 and 291 with an NISS of ≥13. The proportions of amputees and participants with blast injury were both greater in those with higher (NISS ≥13) than lower (NISS <13) trauma scores.

**Venous blood, physiological and metabolic measurements**

Adjusted body mass, AWC, visceral fat area, hs-CRP, triglycerides, platelet count, resting heart rate and cardiac index were significantly higher whereas HDL-cholesterol, eGDR, SVI, 6MWD and physical activity were lower in those in the CRTI group (tables 2 and 3). The prevalence of MetS (18.0% vs 11.8%; adjusted RR, 1.48, 95% CI 1.09 to 1.34, p<0.0001) and cAIx (17.61%±8.79% vs 15.23%±8.19%, p<0.0001) was higher
Cardiac risk factors and prevention

[Image of regression analyses showing risk ratios and coefficients for metabolic syndrome and central augmentation index with combat-related traumatic injury, by injured/uninjured and by injury severity.]

Among the CRTI group versus the uninjured group. The prevalence of MetS and cAIx was significantly higher with worsening injury severity (tables 2 and 3). There were no significant differences in fasting blood glucose, white cell count, HbA1c, blood pressure and PWV between the two groups. The number of participants with AWC, triglyceride and HDL-cholesterol values that fulfilled the defining criteria for MetS was higher in the CRTI group (table 4).

Relationship between cAIx, MetS and cardiovascular risk factors
eGDR, achieved physical activity recommendation and 6MWD were lower whereas age, NISS, hs-CRP, heart rate, brachial and central systolic blood pressure, cAIx and proportion of lower ranks (NS-SEC 2 and 3) were higher in participants with MetS versus those without MetS (table 5).

Age, AWC, visceral fat, triglycerides, hs-CRP, brachial systolic and both diastolic blood pressure and aortic systolic blood pressure all positively correlated with cAIx; HDL-cholesterol, eGDR and 6MWD were inversely correlated (table 6).

Association between traumatic injury, MetS and cAIx
Regression analyses revealed significant associations between CRTI and both MetS and cAIx that were independent not only of age, ethnicity, SEC and time since injury/deployment, but also physical activity (table 7 and figure 1). For each outcome, after adjustment for confounders, the association with CRTI was stronger for those with more severe injuries.

DISCUSSION
In this baseline analysis of the ADVANCE cohort study, we found that CRTI was associated with an increased prevalence of MetS and greater relative large artery stiffness compared with a frequency-matched group of uninjured military combat veterans exposed to the same operational environment. These associations were stronger with greater injury severity. We also observed greater visceral fat area, systemic inflammation (hs-CRP) and lower recommended physical activity among participants with CRTI, which were exacerbated by worsening injury severity. This suggests that CRTI and worsening injury severity may be associated with increased cardiovascular risk.

MetS and arterial stiffness are of major clinical importance given their strong inter-relationship and independent links to MACE. MetS is a complex disorder involving a clustering of cardiovascular risk factors characterised by adipokine release, insulin resistance, renin-angiotensin-aldosterone and sympathetic nervous system activation, oxidative stress, low-grade inflammation and endothelial dysfunction. It predisposes to type 2 diabetes, atherosclerosis and increasing arterial stiffness.

In this study the higher prevalence of MetS in the CRTI group was characterised by greater AWC and triglyceride levels and lower HDL-cholesterol, without notable differences in blood pressure or glucose; again these differences were greater with worsening injury severity. In a recent retrospective study (n=772) of injured US military war veterans of similar age and combat experience to ADVANCE, Bhatnagar et al reported a higher prevalence of MetS among amputees with CRTI compared with a non-amputee CRTI control group. In their study only three (fasting and non-fasted triglycerides, HDL-cholesterol and blood pressure) out of the five established MetS diagnostic criteria were available. The lower eGDR in our study suggests greater relative insulin resistance with CRTI and worsening injury severity. The greater visceral fat area among the participants...
Hence, cAIx is more than just a cardiovascular risk marker and inflammation acting on the arterial wall, leading to a reduction in arterial compliance and increased arterial stiffness.23 Hence, cAIx is more than just a cardiovascular risk marker and can be considered an intermediary outcome measure.23 While PWV and blood pressures were similar, cAIx was significantly higher among the CRTI group and with greater injury severity. As cAIx relates to arterial wave reflection and endothelial function, it may be more vulnerable to earlier changes in arterial haemodynamics and microvascular resistance than PWV.10,22 This could explain why cAIx was greater yet PWV similar in the CRTI group versus the uninjured group. cAIx is one of the strongest independent predictors of future hypertension in adults with normotension and is known to correlate with established cardiovascular risk factors (eg, age, hs-CRP, lipids, lower physical activity and abdominal obesity), as observed in this study, and MACE.24 In a recent meta-analysis of 24 prospective cohort studies (n=146 986), a 10% increase in cAIx was associated with a pooled HR of 1.19 (95% CI 1.05 to 1.34) for all-cause mortality and 1.18 (95% CI 1.09 to 1.27) for MACE.24 We hypothesise that the longitudinal expression of these cardiovascular risk factors in the CRTI group will translate into significantly greater PWV and MACE than that of the uninjured group.

One plausible explanation for the increased burden of MetS and cAIx with CRTI could be their relatively lower physical activity and function (6MWD). Lower physical activity is strongly linked to abdominal obesity, dyslipidaemia, vascular inflammation, insulin resistance, MetS and arterial stiffness.26 In this study CRTI and greater injury severity were associated with lower weekly physical activity and 6MWD. 6MWD was lower with MetS and inversely correlated with cAIx. Lower physical activity was independently associated with cAIx, but not MetS.

Lower SEC has an inverse relationship with adverse cardiovascular health,27 an association apparent for both cAIx and MetS, and independent of injury, in this study. The reasons for this association relate to the interaction of societal factors (eg, childhood deprivation, education, income, access to healthcare) and behaviours (eg, diet and smoking) operating from early life, and even in utero, that act to promote cardiovascular risk.8 27 It is notable that several of the cardiovascular risk factors that were more common in the CRTI group (eg, lower physical activity and HDL-cholesterol and greater triglycerides and abdominal obesity) and linked to lower SEC are modifiable.27 This observation creates the opportunity to introduce targeted prevention strategies to mitigate this risk.

The observation of higher hs-CRP with CRTI is novel. hs-CRP is a marker of systemic inflammation and a mediator of atherosclerosis.28 It has been shown that systemic inflammation leads to a decrease in wave reflections and an increase in cAIx, even in healthy adults.29 In general hs-CRP levels <1.0 mg/L and 1.0–3.0 mg/L are indicative of low and moderate cardiovascular risk, respectively.28 The relatively higher hs-CRP and heart rates in the CRTI group imply greater systemic inflammation and potentially arterial shear stress, which is proatherosclerotic.28

Limitations
This study has a number of limitations. Our findings are based on a cross-sectional analysis of a cohort at its inception and cannot be used to infer causation. Nonetheless, the prospective nature of ADVANCE, the ‘dose’-dependent findings and their biological plausibility are informative in this respect. Based on the distribution of NISS, a value of 13 (the median) was used to categorise injury severity; in a recent US Defense trauma registry of 22 218 patients (injured 2008–2016), this cut-off was the optimal predictor of all-cause mortality and adverse trauma outcomes.30 While our analyses have identified multiple cardiovascular risk markers to be greater in the injured group, average values were still largely within normal ranges. The continuing follow-up of the ADVANCE cohort will be crucial to the understanding of the impact of CRTI on clinical outcomes. Finally, the influence of other potential cardiovascular risk factors/modifiers, such as

Key messages
What is already known on this subject?
► Recent conflicts in Afghanistan and Iraq have led to the survival of injured servicemen with severe injuries than previously would have been very unlikely without modern improvements in combat-related healthcare.
► The longer-term health consequences of these severe traumatic injuries remain unclear.
► A recent systematic review and meta-analysis of searches on PubMed, Embase, ProQuest and Cumulative Index to Nursing and Allied Health Literature databases and Cochrane reviews from 1 January 1980 to 21 December 2018 identified 26 studies that examined the relationship between combat-related traumatic injury (CRTI) and cardiovascular risk.
► The results indicated that the quality and strength of evidence to support the concept are modest, at best, and derived from retrospective cohort studies (n=12) of injuries sustained ≥40 years ago or of small cross-sectional surveys (n=14) without well-defined control groups.
► There is a need for a contemporary prospective study to examine the cardiovascular effects of CRTI.

What might this study add?
► ADVANCE (ArmEd Services Treauma Rehabilitation OutComE) is the first prospective cohort study to examine the relationship between contemporary CRTI and long-term health outcomes.
► The cardiovascular risk profiles, with an emphasis on metabolic syndrome and arterial stiffness, of servicemen who had sustained significant CRTI were compared with an uninjured group of servicemen frequency-matched by age, rank, regiment, role-in-theatre and time of deployment.
► Injury severity was independently, and in an ‘exposure’-dependent manner, associated with both metabolic syndrome and the arterial augmentation index.

How might this impact on clinical practice?
► This study provides evidence that CRTI and its worsening severity are associated with increased early cardiovascular risk with an increase in both metabolic syndrome and arterial stiffness.
► This has important potential implications for the future health of service personnel and others who sustain severe physical trauma.
► The continued follow-up of this cohort will help determine if these findings translate into clinical events and whether targeted primary prevention strategies to the more severely injured might be indicated.

with CRTI and its worsening severity compounds their cardiovascular risk. Increased visceral fat is an independent predictor of MACE.24 cAIx and PWV reflect the cumulative effects of multiple individual cardiovascular risk factors (lipids, glucose, obesity (MetS) and inflammation) acting on the arterial wall, leading to a reduction in arterial compliance and increased arterial stiffness.24 Hence, cAIx is more than just a cardiovascular risk marker and can be considered an intermediary outcome measure.23 While PWV and blood pressures were similar, cAIx was significantly higher among the CRTI group and with greater injury severity. As cAIx relates to arterial wave reflection and endothelial function,
diabetes, psychosocial factors (eg, post-traumatic stress disorder and depression) and chronic pain, has not been examined here but is the subject of further ADVANCE research.

CONCLUSIONS

This study is the first to investigate the relationship between CRI, MetS and arterial stiffness. CRI was independently associated with increased MetS and early markers of arterial stiffness. These risks were more pronounced with worsening injury severity and were independent of age, SEC, physical activity, ethnicity and time from injury. It remains uncertain whether they will translate into MACE over time; this question and the mechanisms behind these associations are the subject of ongoing research within the ADVANCE cohort.

Twitter Christopher J Boos @AdvanceStudy

Acknowledgements We wish to thank all of the research staff at both Headley Court and Stanford Hall who helped with the ADVANCE study, including Seamus Wilson, Molly Waldron, Guy Fraser, Meliya Kaya-Barge, Tass White, Anna Verey, Sarah Evans, Maija Maskuniiti, Lajil Varsani, Helen Prentice, Urszula Puclowska, Helen Blackman, Emma Coady, Melanie Chesnokov and Marie Edwards.

Contributors All authors have provided significant contributions to the manuscript and have approved this revised version. Study design: CJB, PC, NTF, AMJB, DD, ANB. Data collection: CJB, PC, NTF, AMJB, DD, DP, SS, ANB. Data analysis and interpretation: CJB, PC, NTF, AMJB, DD, DP, SS, ANB. Writing: CJB, SS, PC, NTF, ANB. Review and editing: CJB, PC, NTF, AMJB, DD, DP, SS, ANB. Guarantor: ANB.

Funding The ADVANCE study is funded through the ADVANCE Charity. Key contributors to this charity are the Headley Court Charity (principal funder), HM Treasury (LIBOR Grant), Help for Heroes, Nuffield Trust for the Forces of the Crown, Forces in Mind Trust, National Lottery Community Fund, Blesma - The Limbless Veterans and the UK Ministry of Defence.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Ethical approval was granted by the Ministry of Defence Research and Medical Ethics Committee (MoDREC: 357PPE12).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Given the sensitive nature of the participants, the data have not been widely available.

Requests for data will be considered on a case-by-case basis and subject to UK Ministry of Defence clearance.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any errors and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iD Christopher J Boos http://orcid.org/0000-0002-3381-5068

REFERENCES

1. Modan M, Peles E, Haklin H, et al. Increased cardiovascular disease mortality rates in traumatic lower limb amputees. Am J Cardiol 1998;82:1242–7.

2. Huber Z, Ryder RA. Traumatic limb amputations and subsequent mortality from cardiovascular disease and other causes. J Chronic Dis 1980;33:239–50.

3. Kunnas T, Solakivi T, Renko J, et al. Late-life coronary heart disease mortality of Finnish war veterans in the TAMRISK study, a 28-year follow-up. BMC Public Health 2011;11:71.

4. Boos CJ, De Villiers N, Dybball D, et al. The relationship between military combat and cardiovascular risk: a systematic review and meta-analysis. Int J Vasc Med 2019;2019:9840465.

5. Bennett AN, Dyball DM, Boos CJ, et al. Study protocol for a prospective, longitudinal cohort study investigating the medical and psychosocial outcomes of UK combat casualties from the Afghanistan war: the advance study. BMJ Open 2020;10:e037850.

6. Gonzalez-Chávez A, Chávez-Fernández JA, Elizondo-Argüeta S, et al. Metabolic syndrome and cardiovascular disease: a health challenge. Arch Med Res 2018;49:516–21.

7. Grundy SM, Cleeman JL, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American heart Association/National heart, lung, and blood institute scientific statement. Circulation 2005;112:2735–52.

8. Tune JD, Goodwill AG, Sassoen DJ, et al. Cardiovascular consequences of metabolic syndrome. Transl Res 2017;183:57–70.

9. Aminuddin A, Chellappa K, Maskon O, et al. Augmentation index is a better marker for cardiovascular risk in young Malaysian males. A comparison of involvement of pulse wave velocity, augmentation index, and C-reactive protein. Saudi Med J 2014;35:138–46.

10. Schmidt KMT, Hansen KM, Johnson AL, et al. Longitudinal effects of cigarette smoking and smoking cessation on aortic wave reflections, pulse wave velocity, and carotid artery distensibility. J Am Heart Assoc 2019;8:e013939.

11. Bhatnagar V, Richard E, Melear T, et al. Retrospective study of cardiovascular disease risk factors among a cohort of combat veterans with lower limb amputation. Vasc Health Risk Manag 2019;15:409–18.

12. Eftahed H-S, Soroush M-R, Hasani-Ranjbar S, et al. Prevalence of metabolic syndrome and health-related quality of life in war-related bilateral lower limb amputees. J Diabetes Metab Disord 2017;16:17.

13. Tzamaloukas AH, Patron A, Malhotra D. Body mass index in amputees. J Parenter Enteral Nutr 1994;18:355–8.

14. Williams KV, Erbey JR, Becker D, et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000;49:626–32.

15. Osler T, Baker SP, Long W. A modification of the injury severity score that both improves accuracy and simplifies scoring. J Trauma 1997;45:322–6.

16. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med 2020;54:1451–62.

17. Booth M. Assessment of physical activity: an international perspective. Res Q Exerc Sport 2000;71:114–20.

18. Pucci G, Cheriyan J, Hubishi A, et al. Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. J Hypertens 2013;31:77–85.

19. Wilkinson IB, MacCallum H, Flint L, et al. The Influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;525 Pt 1:1263–70.

20. Zhou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–6.

21. Safer ME. Arterial stiffness as a risk factor for clinical hypertension. Nat Rev Cardiol 2018;15:97–105.

22. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation 2021;143:e984–1010.

23. Li W-F, Huang Y-Q, Feng Y-Q. Association between central haemodynamics and risk of all-cause mortality and cardiovascular disease: a systematic review and meta-analysis. Hum Hypertens 2019;33:531–41.

24. Ormazabal V, Nair S, Elley DJ, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018;17:122.

25. Tang KL, Rashid R, Godley J, et al. Association between subjective social status and cardiovascular disease and cardiovascular disease risk factors: a systematic review and meta-analysis. BMJ Open 2016;6:e010137.

26. Buckley DI, Fu R, Freeman M, et al. C-Reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med 2009;151:483–95.

27. Vlachopoulos C, Dima I, Aznauridis K, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005;112:2193–200.

28. Lammers DT, Marenco CW, Morte KR, et al. All trauma is not created equal: redefining severe trauma for combat injuries. Am J Surg 2020;219:869–73.